Tryptamine Therapeutics (AU:TYP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tryptamine Therapeutics has announced successful completion of its Phase 1b trial for TRP-8803, an innovative IV-infused psilocin formulation. The study confirmed the safety and efficacy of TRP-8803 in achieving controlled psychedelic states with faster onset compared to oral psilocybin. This development paves the way for Phase 2 trials, potentially offering new therapeutic options for neuroplastic treatment.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.